Richardcyoung.com

  • Home
  • Debbie Young
  • Jimmy Buffett
  • Key West
  • Your Survival Guy
  • How We Are Different
  • Paris
  • About Us
    • Foundation Principles
    • Contributors
  • Investing
    • You’ve Read The Last Issue of Intelligence Report, Now What?
  • The Swiss Way
  • My Rifles
  • Dividends and Compounding
  • Your Security
  • Dick Young
  • Dick’s R&B Top 100
  • Liberty & Freedom Map
  • Bank Credit & Money
  • Your Survival Guy’s Super States
  • NNT & Cholesterol
  • Your Health
  • Ron Paul
  • US Treasury Yield Curve: My Favorite Investor Tool
  • Anti-Gun Control
  • Anti-Digital Currency
  • Joel Salatin & Alfie Oakes
  • World Gold Mine Production
  • Fidelity & Wellington Since 1971
  • Hillsdale College
  • Babson College
  • Contact Us

India To Be “Production Hub” of Merck’s COVID Wonder-Drug

October 14, 2021 By The Editors

By Fabio Berti @ Shutterstock.com

Merck will produce many of the ingredients for its new COVID drug, Molnupiravir, in India. Reuters reports:

BENGALURU (Reuters) -India’s Everest Organics Ltd said on Tuesday it had started making the active pharmaceutical ingredient (API) for a generic version of Merck & Co’s experimental antiviral drug molnupiravir to treat mild to moderate COVID-19.

Shares of Everest Organics jumped as much as 11.6% after the news came in, and were last up 9.9% at 330 rupees in a weak Mumbai market.

The Indian bulk drugs manufacturer joins Divi’s Laboratories Ltd as an API maker for Merck’s experimental oral drug.

Merck has separately entered into voluntary licensing agreements with at least eight Indian generic drugmakers for molnupiravir, with an aim to turn the country into a manufacturing hub for the drug.

“After the successful development and commercialisation of various COVID-19 drugs such as Oseltamivir, Remdesivir… Everest Organics is on its path of expansion of this portfolio,” Chief Executive Officer Srikakarlapudi Sirisha said in a statement https://bit.ly/3DD49Bn.

Merck said on Monday it had sought U.S. emergency use authorisation for the drug, putting molnupiravir on course to become the first oral antiviral medication for COVID-19.

The U.S. authorisation application was based on data released earlier this month by Merck and partner Ridgeback Biotherapeutics.

Related Posts

  • Logistical Snags Creating Oxygen Shortage Amid India's COVID-19 Spike
  • COVID Deaths Unfortunate but Insignificant
  • Covid-19’s Hidden Hobbies
  • Good COVID News!
  • Author
  • Recent Posts
The Editors
The Editors
The Editors
Latest posts by The Editors (see all)
  • Are California Politicians Abetting the Violence? - June 11, 2025
  • Democrats Slowly Realizing Transgender Campaign Was a Mistake - June 9, 2025
  • Memorial Day Remembrance - May 26, 2025

Dick Young’s Must Reads

  • You May Be Surprised by America’s “Least Woke City”
  • You Need to Seek Some Shelter for When Things Get Ugly
  • “We’re Not Going Back”
  • Meet Me at Freddy’s June 2022
  • Progressive Liberalism Has Dragged America near Ruination
  • BLOOD THINNERS: Is a Big Advance Imminent?
  • Is Rutin Useful in Preventing Blood Clots?
  • Two Americas: The Assassination Attempt on Trump
  • FARM AMERICA: New York City’s Finest Cheesemongers
  • “An Epic Struggle Over the Definition of America”

Our Most Popular Posts

  • Whoa, Hang on Here. There’s Trouble in Culver City
  • Is Salt Bad for You?
  • RON PAUL: Can Musk and Trump Reconcile?
  • $25 Million Down; $175 Million to Go
  • Saving Western Civilization
  • Graduating from Work to Retirement #19: A Teacher for Life
  • No More NSAIDS for Back Pain?
  • There Are Only Two Ways to Cut Entitlements
  • The Federal Reserve Finally Killed the Penny
  • Ukraine’s Attack Underlines Need for Trump-Style Border Control

Compensation was paid to utilize rankings. Click here to read full disclosure.

RSS Youngresearch.com

  • Graduating from Work to Retirement Special Bonus: God Only Knows
  • US Secures LNG Export Deals Worth $200 Billion
  • High-Voltage Cable Crunch Hits Global Electrification
  • May PPI Lower than Expected
  • Graduating from Work to Retirement #20: Life in Reverse
  • US Inflation Eases to 0.1% in May
  • DOE Focuses on Nuclear and AI Innovation
  • Trump Delivers Lower Inflation and Rising Wages
  • Natural Gas Power Growth Slows, but Big Gains Possible by 2028
  • Graduating from Work to Retirement #19: A Teacher for Life

RSS Yoursurvivalguy.com

  • Graduating from Work to Retirement Special Bonus: God Only Knows
  • Private Equity: Moody’s Warns There’s Ample Cause for Concern
  • Your Survival Guy: Castle Hill, Newport
  • Containerized Missiles and the New Rules of War
  • Graduating from Work to Retirement #20: Life in Reverse
  • America’s Silent Army with 423M Guns
  • Top 10 Reasons to Own an AR-15
  • Graduating from Work to Retirement #19: A Teacher for Life
  • Can Luxury Ride AI to Success?
  • Market Timing Could Be Hazardous to Your Portfolio

US Treasury Yield Curve: My Favorite Investor Tool

My Key West Garden Office

Your Retirement Life: Traveling the Efficient Frontier

Live a Long Life

Your Survival Guy’s Mt. Rushmore of Investing Legends

“Then One Day the Grandfather was Gone”

Copyright © 2025 | Terms & Conditions | About Us | Dick Young | Archives